Hanyang Securities
VC Fund
Yongdungpo, South Korea
Hanyang Securities is a financial investment company.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Hanyang Securities invests in
Stages Hanyang Securities invests in
Countries Hanyang Securities invests in
Investment Focus
Industry
- Biotechnology 3 (38%)
- Biopharma 2 (25%)
- Manufacturing 2 (25%)
- Information Technology 2 (25%)
- Art 1 (13%)
Stage
- Series B 2 (25%)
- Venture - Series Unknown 2 (25%)
- Seed 1 (13%)
- Series A 1 (13%)
- Series C 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ire IS
|
Ire IS is an IT company that develops, manufactures, and supplies IT software solutions. | $771.6K / Seed / Jul 28, 2022 | |
SOS LAB
|
SOS Lab, a LiDAR development company focusing on core technology for self-driving cars, plans to present its differentiated hybrid LiDAR system, the SL-1SOS LAB's long-range, hybrid scanning design combines the advantages of the widely-used motor scanning system with a solid-state MEMS mirror, and will be offered at a much lower price pointcompared to traditional LiDAR products on the market today. SL-1 is expected to play an important role in the popularization and accessibility of self-driving cars.In addition to the SL-1, SOS LAB offers two additional LiDAR products designed to integrate safe, effective, and affordable LiDAR technology into various industries: the GL-3 for factory automation and robotics, and the TL-3 for security and automatic doors. SOS LAB is also focusing on combining hardware-based sensors and AI-based object recognition and tracking technology using 3D point cloud LiDAR data, and plans to provide LiDAR data space/object recognition solutions for self-driving vehicles.SOS LAB includes jointly developing their hybrid LiDAR with a partner automotive electronic equipment field company, continuing to develop the next generation of Solid-State-LiDAR with global semiconductor companies to overstep the limits of OPA-method LiDAR, and extending the global footprint of SOS LAB to provide the smartest solutions for self-driving and ADAS markets. SOS LAB is planning to enter global markets based on its R&D centers in Seoul and Gwangju and business centers in Silicon Valley. | $14.8M / Series B / Jul 27, 2022 | |
Openknowl
|
OPENKNOWL is an online career management system, offering mentoring facilities and careers camps for those wanting to develop a career in the IT sector. | $17.2M / Venture - Series Unknown / Feb 11, 2022 | |
Immuneoncia Therapeutics
|
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan (51%) and Sorrento (49%), ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patientsworld-wide. ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 is in Phase 1 clinical trial. Yuhan Corporation is a South Korea-based healthcare company founded in 1926. The company has positioned itself as one of the top pharmaceutical companies in terms of market cap and sales revenue in Korea. The core business consists of primary & specialty care, dietary supplements, household & animal care, and contract manufacturing of active pharmaceutical ingredients. It has a number of subsidiaries and a global presence in the form of joint ventures with Janssen (Belgium), the Clorox Company (USA), and Kimberly-Clark Corporation (USA). Yuhan (000100:KS) is a publicly-listed company traded on the Korea Stock Exchange. | $20.6M / Venture - Series Unknown / Jan 17, 2022 | |
SM Lab
|
SM Lab provides develops and produces anode and cathode materials for secondary batteries. | $38.2M / Series C / Dec 09, 2021 | |
ArtNGuide
|
ArtNGuide conducts online auctions and art fairs. | $7.7M / Series A / Oct 05, 2021 | |
PeopleBio
|
PeopleBio develops diagnosis detection products and specializes in developing diagnostics for protein misfolding diseases. | $33.6M / Post-IPO Equity / Jun 21, 2021 | |
ILIAS Biologics
|
ILIAS Biologics is a biotechnology company that specializes in therapeutic molecules. The company features platform technology that enables experts to load large therapeutic molecules into exosomes. ILIAS Biologics is developing various therapeutic exosomes, a potential treatment for sepsis, pre-term birth, and various hard-to-treat diseases ininflammatory and metabolic areas. | $20.6M / Series B / Sep 28, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hanyang Securities invest in?
Hanyang Securities invests primarily in Biotechnology, Biopharma and Manufacturing startups, most often at Series B and Venture - Series Unknown stage. Most of the 8 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Hanyang Securities last invest?
The most recent investment recorded for Hanyang Securities closed in Jul 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
